1. Scrip

GSK wins $196m US BARDA contract for anthrax antitoxin raxibacumab

 
• By Donna Young

The US government has ordered 60,000 doses of GlaxoSmithKline's anthrax antitoxin raxibacumab under a four-year contract worth $196m with the Biomedical Advanced Research and Development Authority (BARDA).

The US government has ordered 60,000 doses of GlaxoSmithKline's anthrax antitoxin raxibacumab under a four-year contract worth $196m with the Biomedical Advanced Research and Development Authority (BARDA).

The Department of Health and Human Services (HHS) through BARDA is purchasing raxibacumab as a medical countermeasure (MCM) against a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.